Tumour Necrosis Factor (TNF) in Psoriatic Arthritis: Pathophysiology and Treatment with TNF Inhibitors P J Mease
Total Page:16
File Type:pdf, Size:1020Kb
298 REVIEW Ann Rheum Dis: first published as 10.1136/ard.61.4.298 on 1 April 2002. Downloaded from Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors P J Mease ............................................................................................................................. Ann Rheum Dis 2002;61:298–304 High levels of proinflammatory cytokines, including hyperproliferation of psoriasis.12 The cytokines tumour necrosis factor (TNF), have been detected in produced in response to immune activation are also critical contributors to disease pathogenesis. psoriatic skin lesions and joints of patients with the For example, proinflammatory cytokines such as inflammatory disease. Early results of treatment of TNF are found in high levels in the skin lesions psoriatic arthritis and psoriasis with TNF neutralising and plasma of patients with psoriasis.13 In some cases, psoriasis may be triggered by environmen- agents are encouraging, but whether these agents will tal stimuli, such as streptococcal or other infec- be able to improve long term outcomes, such as tion, trauma, or certain drugs.11 14 disability, is not yet known. .......................................................................... “Multiple genetic, immunological, and environmental factors have been implicated in the pathogenesis of PsA.” Agents that neutralise tumour necrosis factor (TNF), a proinflammatory cytokine, have recently Why a subset of patients with psoriasis also been shown to relieve the signs and symptoms of experience PsA joint manifestations is not psoriatic arthritis (PsA).12 The mechanism by known. In approximately 75% of patients with which these agents provide this benefit is related PsA, the appearance of skin lesions precedes to the role of TNF in this chronic inflammatory arthritic symptoms. About 10–15% of patients arthritis. Psoriatic arthritis virtually always have simultaneous onset of psoriasis and PsA, occurs in patients with psoriasis, which is present and another 10–15% show signs of characteristic in 1–3% of the general population.34From 5% to PsA before developing psoriasis. The onset of PsA over 30% of patients with psoriasis develop is typically between 30 and 55 years of age, but a PsA.3 5–7 Although PsA was once considered juvenile form may strike children younger than benign, recent studies have shown that even 5 16. Men and women are equally affected. http://ard.bmj.com/ actively treated patients can have significant joint PsA may have a variety of clinical features that damage and deformity.8 One study showed that can overlap with one another in presentation. 57% of patients had erosive arthritis, and 19% Patients with PsA may present with asymmetrical displayed moderate to severe functional oligoarthritis (fewer than five affected joints); impairment.9 The pathogenesis of PsA remains symmetrical or asymmetrical polyarthritis (five or unclear; however, evidence suggests that disease more affected joints); distal interphalangeal progression is predicted by significant inflamma- 10 (DIP) joint involvement; arthritis mutilans, a tion early in the course of the disease. on September 26, 2021 by guest. Protected copyright. rare, severely deforming type of arthritis (fig 1); FEATURES AND CONSEQUENCES OF and an ankylosing spondylitis-like inflammatory arthritis affecting the spine.31516 Polyarthritis in PSORIASIS AND PSA PsA may be similar to rheumatoid arthritis (RA) The skin lesions of the major form of psoriasis, and is asymmetrical in about half of cases.15 The plaque psoriasis, are typically erythematous pa- onset and relative severity of PsA may not corre- pules topped by a silvery white scale. Other late with the onset and severity of psoriasis in any disease variants include guttate, pustular, and given patient.17 erythrodermic psoriasis. Generally, psoriasis be- Because of its heterogeneous nature, PsA may gins to appear in patients between the ages of 20 be difficult to differentiate from other forms of and 50 years. The papules coalesce to form inflammatory arthritis. Most patients are sero- plaques of varying shapes and patterns, especially negative for rheumatoid factor, so PsA is classified on the elbows, knees, scalp, groin, and nails. as a seronegative spondyloarthropathy, a category Although the cause and pathogenesis of that includes ankylosing spondylitis, Reiter’s dis- psoriasis are unknown, genetic factors, immuno- ....................... ease, and enteropathic arthropathies. However, logical factors, and environmental agents are rheumatoid factor is sometimes found in patients Correspondence to: believed to have a role.11 Certain HLA antigens are ProfessorPJMease, associated with psoriasis, particularly HLA-Cw6 Seattle Rheumatology in white subjects and HLA-A1 and HLA-DR1 in Associates, 1101 Madison ................................................. St, Seattle, WA 98104, Asians, but considerable genetic heterogeneity Abbreviations: DIP, distal interphalangeal; DMARDs, USA; pmease@ exists in these loci among patients with u.washington.edu psoriasis.11 Activation of T lymphocytes, antigen disease modifying antirheumatic drugs; IM, intramuscular; MTX, methotrexate; NSAIDs, non-steroidal presenting cells, and adhesion molecules through Accepted anti-inflammatory drugs; PASI, Psoriasis Area and Severity 15 October 2001 autoimmune mechanisms is believed to play a Index; PsA, psoriatic arthritis; RA, rheumatoid arthritis; ....................... key, probably overlapping, role in the epidermal SSZ, sulfasalazine; TNF, tumour necrosis factor www.annrheumdis.com Tumour necrosis factor in psoriatic arthritis 299 Ann Rheum Dis: first published as 10.1136/ard.61.4.298 on 1 April 2002. Downloaded from Figure 1 Distal interphalangeal joint involvement in the fingers of a patient with arthritis mutilans, a severe form of psoriatic arthritis. with PsA, which complicates the task of distinguishing between PsA and RA, especially as PsA may occur before the appearance of psoriasis symptoms.18 Five clinical subgroups of PsA have been proposed by Moll and Wright: (a) arthritis of DIP joints, (b) arthritis mutilans, (c) symmetrical arthritis Figure 2 Tumour necrosis factor (TNF) expression in a synovial similar to RA but with negative rheumatoid factor, (d) asym- membrane section from an affected joint of a patient with a severe form of psoriatic arthritis, arthritis mutilans (original magnification metrical pauciarticular arthritis with dactylitis, and (e) anky- × 10 16 600). The section was stained with a monoclonal antibody to TNF. losing spondylitis with or without peripheral arthritis. Reproduced from Danning et al, 200027 with permission. Unfortunately, the sensitivity of these criteria is low,19 leading to suggestions that the criteria should be updated.19 20 The definitive diagnosis of PsA remains a complex issue. seen in patients with RA. This difference may be attributed to PsA can result in severe deformity and functional impair- reduced trafficking of immune cells in the joints of patients ment. In one prospective study, 57% of patients were found to with PsA as compared with those with RA, possibly owing to have erosive arthritis, resulting in moderate to severe reduced expression of the adhesion molecule E-selectin in the 24 functional impairment in 19%, at the time of referral to the synovial membranes of patients with PsA. rheumatology clinic.9 Inflammation early in the course of the Cytokines derived primarily from monocytes/macrophages, disease appears to be a significant predictor of disease such as TNF, interleukin 1, interleukin 6, and interleukin 8, are progression. A 14 year prospective study found that a high raised in the synovial fluid and membranes of affected joints 13 26–28 number of effusions upon first presentation at a PsA clinic (fig 2) and in synovial explants. Although most studies correlated with future progression of joint damage, and a low have found that the levels of these cytokines are somewhat erythrocyte sedimentation rate correlated with little disease lower than those found in the joints of patients with RA, the progression.10 The majority of PsA-induced joint damage overall pattern of cytokine expression is similar, suggesting appears to occur early in the course of disease, as indicated by that these intracellular messengers may be general mediators 26 27 the fact that the rate of disease progression slows over time.8 of joint inflammation and destruction. Cytokines produced Although the underlying damage may occur early, the course by the T helper 1 (Th1) subpopulation (for example, http://ard.bmj.com/ γ α of PsA is typically one of cumulatively increasing numbers of interleukin 2, interferon , and lymphotoxin ) are also raised 28 29 affected joints over time. A prospective evaluation found that in the synovial fluids and tissues of patients with PsA. the proportion of patients with five or more damaged joints These results suggest that complex interactions between T doubled from 19% to 41% during the five year study.8 cells and monocytes/macrophages help drive the pathogenesis of PsA.28 PATHOGENESIS As with psoriasis, environmental factors, such as viral and As with psoriasis, multiple genetic, immunological, and envi- bacterial infections, have been implicated in the pathogenesis on September 26, 2021 by guest. Protected copyright. 11 ronmental factors have been implicated in the pathogenesis of of PsA. High levels of antibodies to a streptococcal exotoxin PsA. Immunogenetic phenotyping has disclosed associations and to peptidoglycans, cell